Related Experiment Videos
Stimulation of resistance of immunocompromised mice by a muramyl dipeptide analog
Infection and Immunity
|September 1, 1982
Abstract:
L18-MDP(Ala), a synthetic derivative of muramyl dipeptide, enhanced resistance against Escherichia coli and Candida albicans infections in aged mice and younger adult mice whose defense mechanism(s) had been depressed by X-ray irradiation or by treatment with cyclophosphamide.
Insights
L18-MDP(Ala), a synthetic muramyl dipeptide derivative, boosted immunity against bacterial and fungal infections in mice. This immune enhancement was observed in both aged and immunosuppressed animals.
Area of Science:
- Immunology
- Microbiology
- Pharmacology
Background:
- Muramyl dipeptide (MDP) is a key component of bacterial cell walls.
- MDP derivatives are investigated for their immunomodulatory properties.
- Ageing and immunosuppressive treatments can compromise host defense mechanisms.
Purpose of the Study:
- To evaluate the efficacy of L18-MDP(Ala), a synthetic MDP derivative, in enhancing host resistance.
- To assess L18-MDP(Ala)'s immunomodulatory effects in models of compromised immunity.
Main Methods:
- Administration of L18-MDP(Ala) to aged and immunosuppressed mice.
- Challenge with pathogenic bacteria (Escherichia coli) and fungi (Candida albicans).
- Assessment of survival rates and infection resistance.
Main Results:
- L18-MDP(Ala) significantly enhanced resistance against Escherichia coli infections.
- L18-MDP(Ala) also improved defense against Candida albicans.
- These protective effects were observed in both aged mice and younger mice with suppressed immune systems.
Conclusions:
- L18-MDP(Ala) demonstrates potent immunomodulatory activity.
- It effectively restores or enhances host defense against common pathogens.
- L18-MDP(Ala) holds potential as an immunotherapeutic agent for immunocompromised individuals.